About GenePOC Diagnostics
GenePOC Diagnostics is a Healthcare company based in Quebec City (Canada) founded in 2007, and was acquired by Meridian Bioscience in April 2019. It operates as a point-of-care nucleic acid assays for infectious diseases are developed rapidly. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Prenetics, Karius, Day Zero Diagnostics, OpGen and Clear Labs and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
GenePOC Diagnostics was founded in 2007 in Quebec City, Canada, within the diagnostics sector. Rapid nucleic acid assays for infectious diseases are created for point-of-care use. An automated device is employed, in which a small patient sample is loaded onto a cartridge and inserted into a reader for digital results within one hour. Development focuses on tests for STDs, hospital-acquired infections, respiratory conditions, neonatal sepsis, and gastrointestinal infections.
- Headquarters Quebec City, Canada
- Stage Acquired
- SectorsHealthcare
- Website genepoc-diagnostics.com
- Social LinkedIn
- Acquired by Meridian Bioscience (Apr 2019)
- InvestorsMeridian Bioscience
& 2 more
- Acquired byMeridian Bioscience
(Apr 2019)
Funding Insights of GenePOC Diagnostics
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of GenePOC Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2016 | – | Series B | – | – | |
| Jan 2015 | – | Series A | – | – |
3 investors in total: 3 institutional.
Investors in GenePOC Diagnostics
GenePOC Diagnostics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Meridian Bioscience, Debiopharm and Credit Mutuel Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and VC investments are directed toward multiple sectors. | – | creditmutuelequity.com | Paris, France | |
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs | 1979 | debiopharm.com | Lausanne, Switzerland | |
Molecular diagnostic device and kits | 1976 | meridianbioscience.com | Ohio, United States |
Investor details for GenePOC Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GenePOC Diagnostics
4 dated milestones of GenePOC Diagnostics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded GenePOC Diagnostics is founded.
- Funding First funding round.
- Funding Latest funding round, Series B,.
- Exit Acquired by Meridian Bioscience.
Competitors of GenePOC Diagnostics
GenePOC Diagnostics has 10 listed competitors in our database, 10 of them funded. They include Prenetics, Karius, Day Zero Diagnostics, OpGen and Clear Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| dayzerodiagnostics.com | 2016 | Boston, United States | $48.6M | 48 | Genome sequencing diagnostics for infectious diseases are developed. | |
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| springbankpharm.com | 2002 | Milford, United States | $36.7M | 84 | Viral infection treatments are developed using nucleic acid hybrid chemistry. | |
| availsmedical.com | 2013 | Menlo Park, United States | $8.66M | – | Point-of-care devices are developed for infection diagnosis and treatment optimization. | |
| qvella.com | 2009 | Toronto, Canada | $39.7M | – | Develops innovative platforms for accurate and rapid bacteria diagnosis in healthcare. | |
| curetis.com | 2007 | Holzgerlingen, Germany | $127.14M | 55 | Molecular diagnostics platform is provided for infectious disease detection. | |
| resistell.com | 2017 | Basel, Switzerland | $13.44M | – | Antibiotic susceptibility testing is provided via bacterial movement detection. |
Detailed competitors of GenePOC Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as GenePOC Diagnostics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genepoc Diagnostics
Complete news archive for GenePOC Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenePOC Diagnostics
GenePOC Diagnostics was founded in 2007 and raised its 1st funding round 8 years after it was founded.
GenePOC Diagnostics is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.
GenePOC Diagnostics was founded in 2007 in Quebec City, Canada, within the diagnostics sector. Rapid nucleic acid assays for infectious diseases are created for point-of-care use. An automated device is employed, in which a small patient sample is loaded onto a cartridge and inserted into a reader for digital results within one hour. Development focuses on tests for STDs, hospital-acquired infections, respiratory conditions, neonatal sepsis, and gastrointestinal infections.
GenePOC Diagnostics's top competitors include Prenetics, Clear Labs and Day Zero Diagnostics.
GenePOC Diagnostics has 3 investors. Key investors include Meridian Bioscience, Debiopharm, and Credit Mutuel Equity.
Yes. GenePOC Diagnostics was acquired by Meridian Bioscience in April 2019.